Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Lapatinib plus capecitabine is an effective treatment option for trastuzumab-refractory HER2-positive metastatic breast cancer. We have investigated the correlation between quantitative measures of HER2, p95HER2, and HER3 and treatment outcomes using lapatinib and capecitabine.
Pubmed ID: 22848366
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
Cell line MCF-7 is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentions